Argent BioPharma (ASX:RGT) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

RGT Stoklara Genel Bakış

İlaç keşfi yapan klinik aşamadaki bir biyofarmasötik şirketi olan Argent BioPharma Limited, dünya çapında immünoloji ve nörolojiyi hedef alan ilaçlar sağlamaktadır.

Şirket hakkında

RGT temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Negatif hissedar öz sermayesi

Kazançlar son 5 yılda yılda 6.5% oranında azaldı

Geliri 1 milyon ABD dolarından az ( A$891K )

+ 2 daha fazla risk

Argent BioPharma Limited Rakipler

IDT Australia

ASX:IDT

AU$49.4m

Syntara

ASX:SNT

AU$55.5m

Invion

ASX:IVX

AU$27.1m

Incannex Healthcare

ASX:IHL

AU$65.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Argent BioPharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$0.55
52 Haftanın En Yüksek Seviyesi	AU$2.00
52 Haftanın En Düşük Seviyesi	AU$0.15
Beta	1.05
11 Aylık Değişim	71.88%
3 Aylık Değişim	89.66%
1 Yıllık Değişim	-72.50%
33 Yıllık Değişim	-99.05%
5 Yıllık Değişim	-98.47%
Halka arzdan bu yana değişim	-99.62%

Son Haberler & Güncellemeler

Recent updates

If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns

Feb 21

Hissedar Getirileri

	RGT	AU Pharmaceuticals	AU Pazar
7D	54.9%	-6.3%	-0.7%
1Y	-72.5%	82.1%	17.1%

Getiri vs. Endüstri: RGT geçen yıl % 98.5 oranında getiri sağlayan Australian Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: RGT geçen yıl % 17.9 oranında getiri sağlayan Australian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is RGT's price volatile compared to industry and market?
RGT volatility
RGT Average Weekly Movement	31.4%
Pharmaceuticals Industry Average Movement	10.6%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.7%

İstikrarlı Hisse Senedi Fiyatı: RGT hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: RGT 'nin haftalık oynaklığı ( 31% ) geçen yıl boyunca sabit kaldı, ancak hala Australian hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	n/a	Roby Zomer	argentbiopharma.com

İlaç keşfi yapan klinik aşamadaki bir biyofarmasötik şirketi olan Argent BioPharma Limited, dünya çapında immünoloji ve nörolojiyi hedef alan ilaçlar sunmaktadır. Başlıca ürün adayları arasında SLE Lupus, anti-enflamatuar ve SARS COVID-19 tedavisi için faz II klinik çalışmada olan CimetrA; ve refrakter epilepsi ve serebral palsi için faz I klinik çalışmada olan CannEpil; ve Demans ve Alzheimer'ın semptomatik rahatlaması için faz I klinik çalışmada olan CogniCann bulunmaktadır. Ayrıca, şirket beyin kanseri için Irnican'ı da sunmaktadır.

Argent BioPharma Limited Temel Bilgiler Özeti

Argent BioPharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
RGT temel i̇stati̇sti̇kler
Piyasa değeri	AU$26.62m
Kazançlar(TTM)	-AU$17.53m
Gelir(TTM)	AU$891.08k

29.9x

P/S Oranı

-1.5x

F/K Oranı

RGT aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
RGT gelir tablosu (TTM)
Gelir	AU$891.08k
Gelir Maliyeti	AU$1.20m
Brüt Kâr	-AU$304.15k
Diğer Giderler	AU$17.23m
Kazançlar	-AU$17.53m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.36
Brüt Marj	-34.13%
Net Kâr Marjı	-1,967.34%
Borç/Özkaynak Oranı	-149.0%

RGT uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

RGT Stoklara Genel Bakış

Ödüller

Risk Analizi

Argent BioPharma Limited Rakipler

ASX:IDT

AU$49.4m

ASX:SNT

AU$55.5m

ASX:IVX

AU$27.1m

ASX:IHL

AU$65.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024

Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

New minor risk - Share price stability

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Recent updates

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024

Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

New minor risk - Share price stability

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New major risk - Market cap size

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

New major risk - Market cap size

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million.

MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Board Changes

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 12.4 million.

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New major risk - Shareholder dilution

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New minor risk - Financial data availability

MGC Pharmaceuticals Limited Announces Positive Pre-Clinical Trial Results on CimetrA®

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals Limited Announces Resignation of Arron Canicais, Joint Company Secretary

New major risk - Shareholder dilution

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of £0.65 million.

New major risk - Market cap size

MGC Pharmaceuticals Limited Announces Appointment of Layton Mills as Non-Executive Director

MGC Pharmaceuticals Limited Announces Board Changes, Effective 1 June 2023

First half 2023 earnings released: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022)

MGC Pharmaceuticals Limited Announces Change of CFO

MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director

MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial

Price target decreased to AU$0.04

Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support

MGC Pharmaceuticals Limited Provides an Update on Its Operations

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022

Mgc Pharmaceuticals Limited Announces Board Changes

Full year 2022 earnings: EPS and revenues miss analyst expectations

MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19

MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study

MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial)

Price target decreased to AU$0.07

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC

Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer

MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support

MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19

MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech

MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report

Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer

Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann

MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office

Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer

MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office